Replies to post #242244 on Biotech Values

[RNsidersbuying]

CLBS .65 - I'm still trying to figure out how they arrived at valuation of:

...The transaction values each company at $90 million, which for Caladrius represents a 136% premium to its market cap as of the market close on April 26, 2022...

The CLBS 10-K lists approx. $90M cash. Does the private entity, Cend Therapeutics, also maintain $90M cash on their books?

[DewDiligence]

CLBS—>LSTA (Lisata Therapeutics) at tomorrow’s open, pursuant to previously announced reverse-merger:

https://www.globenewswire.com/news-release/2022/09/14/2515879/18623/en/Caladrius-Biosciences-Announces-Approval-of-Merger-and-Name-Change-to-Lisata-Therapeutics.html